Table 2.
Changes in the purchase value of selected imported drugs (Sanming)
| Change in market share from February 2015 to March 20151 (by value) | |||||
|---|---|---|---|---|---|
|
|
|||||
| Active ingredient | Brand; manufacturer | Dosage form | Feb 2015 [USD] | Mar 2015 [USD] | Δ |
| Amlodipine | Norvasc; Pfizer | 5 mg×7 tab | 45,910.00 | 40,345.20 | −12.1% |
| Cefoperazone/Sulbactam | Sulperazon; Pfizer | 1500 mg×1 vial | 52,635.10 | 44,841.50 | −14.8% |
| Aspirin | Aspirin; Bayer | 100 mg×30 tab | 23,987.40 | 19,630.00 | −18.2% |
| Acarbose | Glucobay; Bayer | 50 mg×30 tab | 68,822.60 | 55,119.00 | −19.9% |
| Cefuroxime | Monocef; Esseti Farmaceutici | 1500 mg×1 vial | 978.20 | 677.20 | −30.8% |
| Atorvastatin | Lipitor; Pfizer | 20 mg×7 tab | 79,886.50 | 36,573.30 | −54.2% |
1
The reported period is the one for which data were collected through the primary research; data for the overall piloting period or other time spans were not available.